For BIO 2011, BioWorld published a list of overused BioCliches to shun, and I was pleased to observe that attendees and speakers must’ve taken notice and avoided using them at BIO 2012 this year. However, since the urge to use…
Category Archives: Biotechnology
Michael’s Personal BIO 2012 Wrap-Up
June 21, 2012 – 6:00 pm
Day One: The wait is over! I leap off the bus and race the other lively stepping attendees to the registration corridor, exchanging pleasantries with everyone I pass. My first-day euphoria high carries me though five sessions, over three miles…
A Stifled U.S. Biotech Sector: Is it Too Late to Recover?
June 20, 2012 – 4:37 pm
BOSTON ‑ Amid all of the excitement that comes with the biopharma industry’s largest annual gathering in Boston this week, I’m worried about the future. The U.S. has lost too much ground ‑ due to the obvious partisan gridlock in…
#BIO2012: Tips for a Wicked Good Meeting
June 14, 2012 – 3:57 pm
Heading to Boston next week for the 2012 Biotechnology Industry Organization International convention? So are we. In fact, BioWorld has attended and exhibited at the annual BIO meeting for 18 years, so we know a thing or two about navigating…
Mamma Mia! It’s Biopharma Season!
June 11, 2012 – 2:48 pm
“Hey kids, let’s put on a show!” That was a famous line from the 1937 Broadway musical, Babes in Arms, shouted to exhort the old gang to take action to save the orphanage. As the theater market just put on…
Big Pharma’s Vanishing Act
April 26, 2012 – 3:01 pm
It wasn’t exactly love at first sight back in 1976 when Genentech Inc. became of legal age to go forth and incorporate, but the platonic relationship between biotech and pharma has increasingly mellowed over the ensuing 36 years into an…
Profit vs. Value: When Activist Shareholders Attack
April 11, 2012 – 3:09 pm
Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
Biotech Fundraising Dips in Q112, But No Need to Panic
April 10, 2012 – 10:48 am
I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year.
2010-12 Biotech IPOs Not Performing THAT Bad. Really.
March 12, 2012 – 3:50 pm
What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty pharma firm Clovis Oncology Inc. shared some surprising similarities in how…
Conference Etiquette – is There an App for That?
March 9, 2012 – 11:21 am
There’s a new contagious condition circulating that has even infected the biotech sector: e-Distraction, with bad manner side effects of indecorum, insensitivity and more. The wealthy are often regarded as egocentric and out of touch with reality by the 99…
Join the Conversation